Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla

• Status: Completed
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

To compare the lipidomic profile in patients with HIV-1 with viral suppression changing efavirenz + emtricitabine + tenofovir (Atripla) to rilpivirine + emtricitabine + tenofovir (Eviplera®) versus a group of patients that continue with Atripla®.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Universitari Vall d'Hebron Research Institute
• Collaborator: Gilead Sciences
• Treatments: Efavirenz; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Tenofovir

Criteria

Inclusion Criteria:

• Patients aged 18 years or above

• Patients infected with HIV-1

• Patients treated with Atripla at least the last 6 months.

• Patients with virologic suppression (HIV RNA <50 copies / ml) for at least the last 6 months.

• Women of childbearing potential must use contraception double barrier.

• Voluntary signature of informed consent

Exclusion Criteria:

• Any acute or chronic (besides chronic HIV-1) disease that could interfere with the analysis of lipidomic

• Women pregnant or lactating

• Abuse of alcohol or other drugs

• Body Mass Index (BMI)> 25

• Use of drugs that may affect lipid metabolism (lipid-lowering drugs, steroids ...)

• Patients unable to understand the study protocol or any other condition that in the investigator's opinion could jeopardize compliance with the protocol

• History or presence of allergy to any of the study drugs or their components